Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response

Davra, Viralkumar; Kimani, Stanley G.; Calianese, David; Birge, Raymond B.
December 2016
Cancers;Dec2016, Vol. 8 Issue 12, p107
Academic Journal
The TAM family of receptors (i.e., Tyro3, Axl, and Mertk), and their ligands Growth arrest specific factor 6 (Gas6) and Protein S (Pros1) contribute to several oncogenic processes, such as cell survival, invasion, migration, chemo-resistance, and metastasis, whereby expression often correlates with poor clinical outcomes. In recent years, there has been great interest in the study of TAM receptors in cancer, stemming both from their roles as oncogenic signaling receptors, as well as their roles in tumor immunology. As a result, several classes of TAM inhibitors that include small molecule tyrosine kinase inhibitors, monoclonal antibodies, decoy receptors, as well as novel strategies to target TAM ligands are being developed. This paper will review the biology of TAM receptors and their ligands with a focus on cancer, as well as evidence-based data for the continued pursuit of TAM/Gas6 inhibitors in clinical practice.


Related Articles

  • Adding cediranib to chemotherapy improves outcomes in patients with advanced cervical cancer. Mayor, Susan // British Journal of Hospital Medicine (17508460);Nov2014, Vol. 75 Issue 11, p610 

    The article discusses results of the phase II clinical trial on the effectiveness of vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor cediranib in improving the treatment outcome of advanced cervical cancer. Topics highlighted include the progression-free and median...

  • First-line therapy for advanced RCC remains controversial amid new approvals: Combination treatment of choice for intermediate-, poor-risk disease not clear, according to expert. Bennett, Christina // Urology Times;Jun2019, Vol. 47 Issue 6, p8 

    The article reports that combination therapy of pembrolizumab and axitinib may not be the standard of treatment for patients with advanced renal cell carcinoma (RCC) despite the approval of pembrolizumab and axitinib by the U.S. Food and Drug Administration (FDA) as a first-line treatment....

  • Sunitinib Induced Immune Thrombocytopenia. Shekarriz, Ramin; Koulaeinejad, Neda; Nosrati, Anahita; Salehifar, Ebrahim // Iranian Journal of Pharmaceutical Research;Autumn2015, Vol. 14 Issue 4, p1295 

    Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and advanced pancreatic neuroendocrine tumors. It has several adverse reactions on multi organ...

  • A New Approach to the Treatment of Metastatic Paraganglioma: Sorafenib. Gunaldi, Meral; Kara, Ismail Oguz; Duman, Berna Bozkurt; Afsar, Cigdem Usul; Ergin, Melek; Avci, Arbil // Cancer Research & Treatment;2014, Vol. 46 Issue 4, p411 

    Paragangliomas are relatively rare chromaffin cell tumors which may be cured through resection. Patients with paragangliomas may develop metastatic diseases. There is no consensus regarding refractory chemotherapy for treatment of metastatic disease. In this report, we presented a case of a...

  • 非小细胞肺癌EGFR-TKI治疗临床获益后 颅内转移机制研究进展. 蒋娟; 胡成平 // Chinese Journal of Lung Cancer;8/20/2015, Vol. 18 Issue 8, p518 

    Currently epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is widely used for treatment of non-small cell lung cancer (NSCLC) patients with EGFR mutation. However, intracranial metastasis and progression could happen to some patients while their primary tumors in lung...

  • Therapeutic Targeting of Fibroblast Growth Factor Receptors in Gastric Cancer. Inokuchi, Mikito; Fujimori, Yoshitaka; Otsuki, Sho; Sato, Yuya; Nakagawa, Masatoshi; Kojima, Kazuyuki // Gastroenterology Research & Practice;4/27/2015, Vol. 2015, p1 

    Chemotherapy has become the global standard treatment for patients with metastatic or unresectable gastric cancer (GC), although outcomes remain unfavorable. Many molecular-targeted therapies inhibiting signaling pathways of various tyrosine kinase receptors have been developed, and monoclonal...

  • Sorafenib in metastatic radioactive iodine-refractory differentiated thyroid cancer: A pilot study. YANG LUO; YUANKAI SHI; PUYUAN XING; LIN WANG; YUN FENG; XIAOHONG HAN; XIAOHUI HE // Molecular & Clinical Oncology;2014, Vol. 2 Issue 1, p87 

    The incidence and mortality of thyroid cancer are on the increase worldwide and the treatment options for progressive, radioactive iodine (RAI)-refractory metastatic differentiated thyroid cancer (DTC) patients are currently limited. Sorafenib is a multikinase inhibitor that targets several...

  • Sunitinib in metastatic thymic carcinomas: laboratory findings and initial clinical experience. Ströbel, P.; Bargou, R.; Wolff, A.; Spitzer, D.; Manegold, C.; Dimitrakopoulou-Strauss, A.; Strauss, L.; Sauer, C.; Mayer, F.; Hohenberger, P.; Marx, A.; Ströbel, P // British Journal of Cancer;7/13/2010, Vol. 103 Issue 2, p196 

    Background: Thymic carcinoma (TC) is a rare aggressive tumour. Median survival with current treatments is only 2 years. Sunitinib is a multi-targeted tyrosine kinase inhibitor that has shown benefit in various other cancers.Methods: Laboratory analyses of snap-frozen...

  • Penetrating the evidence of EGFR and ALK tyrosine kinase inhibitors for non-small cell lung cancer brain metastases. Thomas, Christan M.; Lee, Chung-Shien // Journal of Oncology Pharmacy Practice;Apr2019, Vol. 25 Issue 3, p623 

    The brain is a common metastatic site in lung cancer. Approximately one-third of patients will develop brain metastases during the course of their disease. Median overall survival has been reported between 3 and 14.8 months in patients with brain metastases compared to other metastatic sites. In...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics